Skip to main content

4 Novel Drug Classes Demonstrate Early Promise for EGFR-Mutated NSCLC

*July 2021*

Osimertinib (Tagrisso) has emerged as the standard of care for patients with EGFR-mutated non–small cell lung cancer (NSCLC), but the need for novel agents is underscored as disease progression on the agent is inevitable, according to Karen Kelly, MD. To this end, bispecific antibodies, antibody-drug conjugates (ADCs), EGF vaccines, and fourth-generation EGFR TKIs are all under development and showing early potential to enrich the treatment paradigm.

“It is really important that we develop novel classes of EGFR inhibitors beyond the TKIs for the treatment of [patients with] EGFR-mutated lung cancer,” Kelly, the associate director for Clinical Research at University of California Davis Comprehensive Cancer Center, said in a presentation during the 22nd Annual International Lung Cancer Congress.1 “As we consider the future, and we think about having more agents, [we have several] questions. How do we combine them? Are we headed to triple-drug combinations in the first-line setting? Quadruple-drug combinations? How do we then sequence these? What’s going to be the optimal strategy to help our patients in their cancer journey to make them live longer?”

Read more.